
The FDA approves anifrolumab-fnia injection (Saphnelo; AstraZeneca) for the treatment of adults with moderate to severe system- ic lupus erythematosus (SLE) who are receiving standard therapy.

The FDA approves anifrolumab-fnia injection (Saphnelo; AstraZeneca) for the treatment of adults with moderate to severe system- ic lupus erythematosus (SLE) who are receiving standard therapy.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses her hopes for the future of SHC’s diabetes DRIVE program and its adoption within health systems.

Gallstones range in size from as small as a grain of sand to as large as a golf ball.

Promoting a positive organizational culture is an essential requirement for the effective management of a community pharmacy.

The increasing economic burden of treatment may impact patient outcomes.

Study predicts the future of antibody testing may move toward technologically advanced platforms that can test for multiple antibody types in a single blood sample.

Galactorrhea usually occurs in women, even those who have never had children, or after menopause.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, provides some closing thoughts on sex and gender in health care.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the problems with approaching public health issues, such as mental health and substance use disorders, with an industrialized approach to problem solving.

The goal of the financial counselor is to identify available funding for patient care in a timely manner, but the sheer number of resources and variables involved results in a long, tedious process.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Fibroadenoma may feel like a marble in the breast, moving easily under the skin when examined.

Sarah Temkin, MD, of the Office of Research on Women’s Health at the National Institutes of Health, discusses some key points for pharmacists on the impact of biological and sociological variables on treatment outcomes.

Tom Hanzel, PharmD, MBA, discussed how vaccine mandates impact staffing shortages in long-term care facilities.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.

According to a Kaiser Permanente research study, individuals who received COVID-19 vaccination had lower non-COVID-19 death rates than individuals who were unvaccinated.

Tom Hanzel, PharmD, MBA, of Parata Systems, discussed challenges in pharmacy workflow and how automation could offer solutions.

They can create innovative face-to-face and virtual medication therapy management practices.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the next steps for clinical research assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses some of NIH ORWH’s upcoming goals and projects on the horizon that may impact the pharmacy field.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.

More transparent drug pricing could improve patient care.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.

The FDA looks to address a lack of diversity in cancer drug trials.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.

Andrew Mulcahy, PhD, a senior policy researcher at RAND Corporation, discusses a recent report that showed the drug shortages in the United States may not be associated with problems in the global supply chain.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses how the diabetes DRIVE program compares with the SHC DRIVE models for flu and COVID-19 vaccinations.

Chronic hypersensitivity pneumonitis is a long-term lung condition in which the interstitial tissue surrounding the alveoli of the lungs becomes inflamed and develops fibrosis.